SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

NGL Fine-Chem - Quaterly Results

02 May 2022 Evaluate
The revenue for the March 2022 quarter is pegged at Rs. 782.13 millions, about 8.95% up against Rs. 717.89 millions recorded during the year-ago period.Net profit of the cmpany stood at Rs. 78.58 millions for the quarter ended March 2022 a decline of -45.08% from Rs. 143.07 millions  in the same quarter last year.The company reported a degrowth in operating Profit to 122.72 millions from 233.54 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 782.13 717.89 8.95 3186.67 2552.07 24.87 3186.67 2552.07 24.87
Other Income 22.79 25.35 -10.10 126.40 115.21 9.71 126.40 115.21 9.71
PBIDT 122.72 233.54 -47.45 782.09 852.30 -8.24 782.09 852.30 -8.24
Interest 3.74 3.27 14.37 15.62 18.40 -15.11 15.62 18.40 -15.11
PBDT 118.98 230.27 -48.33 766.47 833.90 -8.09 766.47 833.90 -8.09
Depreciation 18.80 18.52 1.51 76.73 73.94 3.77 76.73 73.94 3.77
PBT 100.18 211.75 -52.69 689.74 759.96 -9.24 689.74 759.96 -9.24
TAX 21.60 68.68 -68.55 167.28 205.28 -18.51 167.28 205.28 -18.51
Deferred Tax -8.90 2.08 -527.88 -4.22 14.58 -128.94 -4.22 14.58 -128.94
PAT 78.58 143.07 -45.08 522.46 554.68 -5.81 522.46 554.68 -5.81
Equity 30.89 30.89 0.00 30.89 30.89 0.00 30.89 30.89 0.00
PBIDTM(%) 15.69 32.53 -51.77 24.54 33.40 -26.51 24.54 33.40 -26.51

NGL Fine-Chem Share Price

2327.95 98.20 (4.40%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×